litlas
Log inCreate account

Jay D. Horton

Active 1993–2024

90
Papers
44,978
Citations
79
h-index
89
i10-index

Citations

Citations per year for Jay D. Horton1986: 1 citations1991: 1 citations1992: 1 citations1993: 2 citations1994: 2 citations1995: 8 citations1996: 10 citations1997: 38 citations1998: 82 citations1999: 125 citations2000: 168 citations2001: 186 citations2002: 276 citations2003: 294 citations2004: 414 citations2005: 409 citations2006: 457 citations2007: 445 citations2008: 605 citations2009: 596 citations2010: 520 citations2011: 566 citations2012: 568 citations2013: 580 citations2014: 583 citations2015: 537 citations2016: 477 citations2017: 593 citations2018: 487 citations2019: 1,460 citations2020: 1,532 citations2021: 1,567 citations2022: 1,183 citations2023: 991 citations2024: 1,443 citations2025: 639 citations2026: 26 citations1987–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,296 citing papers, 28% of this breakdownChina: 2,393 citing papers, 12.7% of this breakdownUnited Kingdom: 1,029 citing papers, 5.5% of this breakdownItaly: 854 citing papers, 4.5% of this breakdownGermany: 806 citing papers, 4.3% of this breakdownCanada: 696 citing papers, 3.7% of this breakdownJapan: 652 citing papers, 3.5% of this breakdownFrance: 645 citing papers, 3.4% of this breakdownAustralia: 497 citing papers, 2.6% of this breakdownSpain: 477 citing papers, 2.5% of this breakdownNetherlands: 461 citing papers, 2.4% of this breakdownSouth Korea: 435 citing papers, 2.3% of this breakdown
0%28%Other 24.6%

Institutions

Fields

  • Medicine62.2%
  • Biochemistry, Genetics and Molecular Biology28.3%
  • Immunology and Microbiology2%
  • Neuroscience2%
  • Nursing1.8%
  • Agricultural and Biological Sciences1.5%
  • Other2.2%

Topics

  • Liver Disease Diagnosis and Treatment9.1%
  • Cholesterol and Lipid Metabolism5.2%
  • Lipoproteins and Cardiovascular Health4.8%
  • Diet, Metabolism, and Disease3.6%
  • Peroxisome Proliferator-Activated Receptors3.4%
  • Diabetes, Cardiovascular Risks, and Lipoproteins3.2%
  • Other70.7%

Coauthors

All papers

Open in search
  1. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

    Authors: Brian A. Ference, Henry N. Ginsberg, Ian Graham, Kausik K. Ray, Chris J. Packard, Éric Bruckert, Robert A. Hegele, Ronald M. Krauss, Frederick J. Raal, Heribert Schunkert, Gerald F. Watts, Jan Borén, Sergio Fazio, Jay D. Horton, L. Masana, Stephen J. Nicholls, Børge G. Nordestgaard, Bart van de Sluis, Marja‐Riitta Taskinen, Lâle Tokgözoğlu, Ulf Landmesser, Ulrich Laufs, Olov Wiklund, Jane K. Stock, M. John Chapman, Alberico L. Catapano - European Heart Journal 2017 cited by 3,840

  2. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel

    Authors: Jan Borén, M. John Chapman, Ronald M. Krauss, Chris J. Packard, Jacob Fog Bentzon, Christoph J. Binder, Mat J.A.P. Daemen, Linda L. Demer, Robert A. Hegele, Stephen J. Nicholls, Børge G. Nordestgaard, Gerald F. Watts, Éric Bruckert, Sergio Fazio, Brian A. Ference, Ian Graham, Jay D. Horton, Ulf Landmesser, Ulrich Laufs, L. Masana, Gerard Pasterkamp, Frederick J. Raal, Kausik K. Ray, Heribert Schunkert, Marja‐Riitta Taskinen, Bart van de Sluis, Olov Wiklund, Lâle Tokgözoğlu, Alberico L. Catapano, Henry N. Ginsberg - European Heart Journal 2020 cited by 1,527

  3. Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association

    Authors: P. Barton Duell, Francine K. Welty, Michael Miller, Alan Chait, Gmerice Hammond, Zahid Ahmad, David E. Cohen, Jay D. Horton, Gregg S. Pressman, Peter P. Toth - Arteriosclerosis Thrombosis and Vascular Biology 2022 cited by 645

  4. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

    Authors: Jay D. Horton, Joseph L. Goldstein, Michael S. Brown - Journal of Clinical Investigation 2002 cited by 4,316

  5. Human Fatty Liver Disease: Old Questions and New Insights

    Authors: Jonathan C. Cohen, Jay D. Horton, Helen H. Hobbs - Science 2011 cited by 2,088

  6. Acetate Dependence of Tumors

    Authors: Sarah A. Comerford, Zhi‐Guang Huang, Xinlin Du, Yun Wang, Ling Cai, Agnes K. Witkiewicz, Holly C. Walters, Mohammed Noor Tantawy, Allie Fu, H. Charles Manning, Jay D. Horton, Robert E. Hammer, Steven L. McKnight, Benjamin P. Tu - Cell 2014 cited by 695

  7. Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity

    Authors: Jeffrey D. Browning, Lidia S. Szczepaniak, Robert L. Dobbins, Pamela Nuremberg, Jay D. Horton, Jonathan C. Cohen, Scott M. Grundy, Helen H. Hobbs - Hepatology 2004 cited by 3,664

  8. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9

    Authors: Kevin Fitzgerald, Suellen White, Anna Borodovsky, Brian R. Bettencourt, Andrew Strahs, Valerie A. Clausen, Peter Wijngaard, Jay D. Horton, Jörg Täubel, Ashley Brooks, Chamikara Fernando, Robert S. Kauffman, David Kallend, Akshay Vaishnaw, Amy Simon - New England Journal of Medicine 2016 cited by 760

  9. Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation

    Authors: Chai-Wan Kim, Carol Addy, Jun Kusunoki, Norma N. Anderson, Stanisław Deja, Xiaorong Fu, Shawn C. Burgess, Li Cai, Marcie Ruddy, Manu V. Chakravarthy, Steve Previs, Stuart Milstein, Kevin Fitzgerald, David E. Kelley, Jay D. Horton - Cell Metabolism 2017 cited by 413

  10. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

    Authors: Jay D. Horton, Nila Shah, Janet A. Warrington, Norma N. Anderson, Sahng Wook Park, Michael S. Brown, Joseph L. Goldstein - National Academy of Sciences, Proceedings of the National Academy of Sciences 2003 cited by 1,444

  11. Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism

    Authors: Heather A. Ferris, Rachel J. Perry, Gabriela Moreira, Gerald I. Shulman, Jay D. Horton, C. Ronald Kahn - National Academy of Sciences, Proceedings of the National Academy of Sciences 2017 cited by 238

  12. Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation

    Authors: Dawei Zhang, Thomas A. Lagace, Rita Garuti, Zhenze Zhao, Meghan McDonald, Jay D. Horton, Jonathan C. Cohen, Helen H. Hobbs - Journal of Biological Chemistry 2007 cited by 784

  13. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

    Authors: Kevin Fitzgerald, Maria Frank-Kamenetsky, Svetlana Shulga‐Morskaya, Abigail Liebow, Brian R. Bettencourt, Jessica E. Sutherland, Renta Hutabarat, Valerie A. Clausen, Verena Karsten, Jeffrey Cehelsky, Saraswathy V. Nochur, Victor Kotelianski, Jay D. Horton, Timothy Mant, Joseph Chiesa, James M. Ritter, Malathy Munisamy, Akshay Vaishnaw, Jared Gollob, Amy Simon - The Lancet 2013 cited by 574

  14. DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER

    Authors: Shunxing Rong, Mingfeng Xia, Gonçalo Vale, Simeng Wang, Chai-Wan Kim, Shili Li, Jeffrey G. McDonald, Arun Radhakrishnan, Jay D. Horton - Cell Metabolism 2024 cited by 91

  15. Interplay between ChREBP and SREBP-1c coordinates postprandial glycolysis and lipogenesis in livers of mice

    Authors: Albert G. Linden, Shili Li, Hwa Young Choi, Fei Fang, Masashi Fukasawa, Kosaku Uyeda, Robert E. Hammer, Jay D. Horton, Luke J. Engelking, Guosheng Liang - Journal of Lipid Research 2018 cited by 230

  16. The Scap/SREBP Pathway Is Essential for Developing Diabetic Fatty Liver and Carbohydrate-Induced Hypertriglyceridemia in Animals

    Authors: Young-Ah Moon, Guosheng Liang, Xuefen Xie, Maria Frank-Kamenetsky, Kevin Fitzgerald, Victor Koteliansky, Michael S. Brown, Joseph L. Goldstein, Jay D. Horton - Cell Metabolism 2012 cited by 316

  17. CCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDL

    Authors: Paulina Bartuzi, Daniel D. Billadeau, Robert P. Favier, Shunxing Rong, Daphne Dekker, Alina Fedoseienko, Hille Fieten, Melinde Wijers, Johannes H.M. Levels, Nicolette Huijkman, Niels Kloosterhuis, Henk van der Molen, Gemma Brufau, Albert K. Groen, Alison M. Elliott, Jan Albert Kuivenhoven, Barbara Plecko, Gernot Grangl, Julie McGaughran, Jay D. Horton, Ezra Burstein, Marten H. Hofker, Bart van de Sluis - Nature Communications 2016 cited by 231

  18. Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice

    Authors: Shunxing Rong, Vı́ctor Cortés, Shirya Rashid, Norma N. Anderson, Jeffrey G. McDonald, Guosheng Liang, Young-Ah Moon, Robert E. Hammer, Jay D. Horton - eLife 2017 cited by 136

  19. PCSK9: a convertase that coordinates LDL catabolism

    Authors: Jay D. Horton, Jonathan C. Cohen, Helen H. Hobbs - Journal of Lipid Research 2008 cited by 631

  20. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and inlivers of parabiotic mice

    Authors: Thomas A. Lagace, David E. Curtis, Rita Garuti, Markey McNutt, Sahng Wook Park, Heidi Prather, Norma N. Anderson, Y K Ho, Robert E. Hammer, Jay D. Horton - Journal of Clinical Investigation 2006 cited by 671

  21. Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound Heterozygote

    Authors: Zhenze Zhao, Yetsa Tuakli-Wosornu, Thomas A. Lagace, Lisa N. Kinch, Nicholas V. Grishin, Jay D. Horton, Jonathan C. Cohen, Helen H. Hobbs - The American Journal of Human Genetics 2006 cited by 633

  22. Genetic and Metabolic Determinants of Plasma PCSK9 Levels

    Authors: Susan G. Lakoski, Thomas A. Lagace, Jonathan C. Cohen, Jay D. Horton, Helen H. Hobbs - The Journal of Clinical Endocrinology & Metabolism 2009 cited by 532

  23. Molecular basis for LDL receptor recognition by PCSK9

    Authors: Hyock Joo Kwon, Thomas A. Lagace, Markey McNutt, Jay D. Horton, J. Deisenhofer - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 414

  24. Hepatic malonyl-CoA synthesis restrains gluconeogenesis by suppressing fat oxidation, pyruvate carboxylation, and amino acid availability

    Authors: Stanisław Deja, Justin A. Fletcher, Chai-Wan Kim, Blanka Kucejová, Xiaorong Fu, Monika Mizerska, Morgan Villegas, Natalia Pudełko‐Malik, Nicholas Browder, Melissa R. Iñigo, Cameron J. Menezes, Prashant Mishra, Eric D. Berglund, Jeffrey D. Browning, John P. Thyfault, Jamey D. Young, Jay D. Horton, Shawn C. Burgess - Cell Metabolism 2024 cited by 59